Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis

Overview of attention for article published in Therapeutics and Clinical Risk Management, July 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

blogs: 1 blog
twitter: 4 X users

facebook: 1 Facebook page
wikipedia: 2 Wikipedia pages

Citations

dimensions_citation: 59 Dimensions

Readers on

mendeley: 118 Mendeley

Summary Blogs X Facebook Wikipedia Dimensions citations

So far, Dimensions has found 59 publications that cite this research output.

59

The most recent citing publications are shown below. View all 59 publications that cite this research output on Dimensions.

IDH-mutant astrocytoma arising from a demyelinating plaque in a child with X-linked adrenoleukodystrophy

Article in Journal of Neuropathology & Experimental Neurology (March 2024)

Riesgo de Cáncer Cutáneo Asociado a Terapias Modificadoras de la Enfermedad en la Esclerosis Múltiple: Revisión Narrativa de la Evidencia Actual

Article in Actas Dermo-Sifiliográficas (February 2024)

Alemtuzumab‐induced petechiae and epistaxis in a patient with relapsing–remitting multiple sclerosis: A case report

Article in Clinical Case Reports (November 2023)